MedTrace Logo

Impact of Neuromodulation on Language Impairments in Stroke Patients

NCT03699930 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-07-07

No results posted yet for this study

Summary

Up to 40% of stroke survivors suffer from aphasia, making recovery of language abilities a top priority in stroke rehabilitation. Conventional speech and language therapy may have limited effectiveness. Leveraging multimodal data (behavioral, neuroimaging, and genetics), this study aims to 1) evaluate the efficacy of combining tDCS with speech therapy, 2) examine neural changes associated with recovery, 3) identify factors influencing response to treatment.

Conditions

Interventions

DEVICE

tDCS

Anodal or sham tDCS will be applied to the scalp.

BEHAVIORAL

Speech and language therapy

A trained speech pathologist will administer the speech and language therapy.

Sponsors & Collaborators

  • Casa Colina Hospital and Centers for Healthcare

    lead OTHER

Principal Investigators

  • Amy Zheng, PhD · Casa Colina Hospital and Centers for Healthcare

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2022-09-01
Completion
2023-01-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03699930 on ClinicalTrials.gov